ArticlePloS one2024

Alpha-fetoprotein and des-gamma-carboxy prothrombin can predict the objective response of patients with hepatocellular carcinoma receiving durvalumab plus tremelimumab therapy.

Issei Saeki et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.